StockNews.com lowered shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) from a hold rating to a sell rating in a research report released on Saturday morning. A number of other brokerages have also recently issued reports on CRBP. Royal Bank of Canada assumed coverage on Corbus Pharmaceuticals in a research report on Monday, May 13th. […]
Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) had its price objective increased by Oppenheimer from $20.00 to $51.00 in a research note published on Monday, Benzinga reports. Oppenheimer currently has an outperform rating on the biopharmaceutical company’s stock. Separately, StockNews.com started coverage on shares of Corbus Pharmaceuticals in a research report on Friday, January 26th. They […]
Corbus Pharmaceuticals (NASDAQ:CRBP) Now Covered by Analysts at StockNews com themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
StockNews.com started coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research report sent to investors on Monday. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Corbus Pharmaceuticals Trading Up 6.5 % NASDAQ:CRBP opened at $6.16 on Monday. The company has a market capitalization of $27.25 million, a P/E […]
StockNews.com began coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a report published on Saturday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Corbus Pharmaceuticals Stock Performance Shares of NASDAQ CRBP opened at $5.55 on Friday. The company has a market cap of $24.53 million, a PE ratio […]